The European molecular oncology diagnostics sector is experiencing significant growth, driven by several key factors. Rising incidence rates of cancer across Europe, coupled with advancements in molecular diagnostic technologies, are stimulating demand for precise and reliable diagnostic tools. Furthermore, the integration of personalized medicine